Literature DB >> 15859832

The American Society of Clinical Oncology program to improve end-of-life care.

T J Smith1, L J Schnipper.   

Abstract

Too few cancer patients have optimal care at the end of life, as measured by unrelieved pain, death in a setting other than home, and uncoordinated care. The American Society of Clinical Oncology (ASCO), as the largest professional society whose members care for most cancer patients in the United States, has begun an initiative to improve end-of-life care. Educational programs for ASCO members have been started at the national level. A Task Force on End of Life Care was created to study the current state of end-of-life care, barriers to improved end-of-life care, and what ASCO can do to improve end-of-life care. A member-wide survey has been completed to assess, from the professional's perspective, the current state of and barriers to end-of-life care. Specific sections of the Task Force will address hospice care, physician- assisted suicide, clinical barriers, economic barriers, research initiatives, educational deficiencies, and quality of care at the end of life. Improvements in end-of-life care can be made if the current deficiencies are noted, barriers ascertained, and specific solutions found. Professional societies have both the interest and responsibility to improve end-of-life care.

Entities:  

Year:  1998        PMID: 15859832     DOI: 10.1089/jpm.1998.1.221

Source DB:  PubMed          Journal:  J Palliat Med        ISSN: 1557-7740            Impact factor:   2.947


  10 in total

1.  Patterns of hospice use in patients dying from hematologic malignancies.

Authors:  Amy Sexauer; M Jennifer Cheng; Louise Knight; Anthony W Riley; Lauren King; Thomas J Smith
Journal:  J Palliat Med       Date:  2014-01-02       Impact factor: 2.947

2.  Commentary: "the Lake Wobegon effect, a natural human tendency to overestimate one's capabilities" (Wikipedia).

Authors:  Thomas J Smith
Journal:  Milbank Q       Date:  2013-12       Impact factor: 4.911

3.  Doing palliative care in the oncology office.

Authors:  M Jennifer Cheng; Lauren M King; Erin R Alesi; Thomas J Smith
Journal:  J Oncol Pract       Date:  2013-03       Impact factor: 3.840

4.  Hospice care and survival among elderly patients with lung cancer.

Authors:  Akiko M Saito; Mary Beth Landrum; Bridget A Neville; John Z Ayanian; Jane C Weeks; Craig C Earle
Journal:  J Palliat Med       Date:  2011-07-18       Impact factor: 2.947

5.  Comparing baseline symptom severity and demographics over two time periods in an outpatient palliative radiotherapy clinic.

Authors:  Luluel Khan; Justin Kwong; Janet Nguyen; Edward Chow; Liying Zhang; Shaelyn Culleton; Liang Zeng; Florencia Jon; May Tsao; Elizabeth Barnes; Cyril Danjoux; Arjun Sahgal; Lori Holden
Journal:  Support Care Cancer       Date:  2011-03-01       Impact factor: 3.603

6.  Timing of palliative care referral and symptom burden in phase 1 cancer patients: a retrospective cohort study.

Authors:  David Hui; Henrique Parsons; Linh Nguyen; Shana L Palla; Sriram Yennurajalingam; Razelle Kurzrock; Eduardo Bruera
Journal:  Cancer       Date:  2010-09-15       Impact factor: 6.860

7.  Variations Among Physicians in Hospice Referrals of Patients With Advanced Cancer.

Authors:  Xiao Wang; Louise S Knight; Anne Evans; Jiangxia Wang; Thomas J Smith
Journal:  J Oncol Pract       Date:  2017-02-21       Impact factor: 3.840

8.  The role of chemotherapy at the end of life: "when is enough, enough?".

Authors:  Sarah Elizabeth Harrington; Thomas J Smith
Journal:  JAMA       Date:  2008-06-11       Impact factor: 56.272

9.  Under-diagnosis of pain by primary physicians and late referral to a palliative care team.

Authors:  Masako Akashi; Eiji Yano; Etsuko Aruga
Journal:  BMC Palliat Care       Date:  2012-06-07       Impact factor: 3.234

10.  End-of-Life Characteristics Associated With Short Hospice Length of Stay for Patients With Solid Tumors Enrolled in Phase I Clinical Trials.

Authors:  Ramy Sedhom; Amanda L Blackford; Arjun Gupta; Kelly Griffiths; Janet Heussner; Michael A Carducci
Journal:  J Natl Compr Canc Netw       Date:  2021-01-21       Impact factor: 11.908

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.